TY  - GEN
AU  - Decara, Juan M
AU  - Pavón, Francisco Javier
AU  - Suárez, Juan
AU  - Romero-Cuevas, Miguel
AU  - Baixeras, Elena
AU  - Vázquez, Mariam
AU  - Rivera, Patricia
AU  - Gavito, Ana L
AU  - Almeida, Bruno
AU  - Joglar, Jesús
AU  - de la Torre, Rafael
AU  - Rodríguez de Fonseca, Fernando
AU  - Serrano, Antonia
PY  - 2015
DO  - 10.1242/dmm.019919
SN  - 1754-8403
UR  - http://hdl.handle.net/20.500.12105/17100
AB  - Fatty liver disease is one of the main hepatic complications associated with obesity. To date, there are no effective treatments for this pathology apart from the use of classical fibrates. In this study, we have characterized the in vivo effects of a...
LA  - eng
PB  - Company of Biologists
KW  - Obesity
KW  - Non-alcoholic fatty liver disease
KW  - Zucker rats
KW  - Cannabinoid type 1 receptor
KW  - CB1
KW  - Peroxisome proliferator activated-receptor α
KW  - PPAR-α
KW  - Ratas zucker
KW  - Ácidos fíbricos
KW  - Homeostasis
KW  - Metabolismo liídico
KW  - Modelos animales
KW  - Obesidad
KW  - Ácido oleico
KW  - ARN mensajero
KW  - Tinción y etiquetado
KW  - Triglicéridos
KW  - Amphetamines
KW  - Rats
KW  - Cannabinoids
KW  - Cytochromes
KW  - Fibric Acids
KW  - Homeostasis
KW  - Lipid Metabolism
KW  - Models, Animal
KW  - Obesity
KW  - Oleic Acids
KW  - RNA, Messenger
KW  - Rats, Zucker
TI  - Treatment with a novel oleic-acid-dihydroxyamphetamine conjugation ameliorates non-alcoholic fatty liver disease in obese Zucker rats.
TY  - research article
ER  -